Implantable device could allow doctors to test cancer drugs in patients before prescribing chemotherapy
More than 100 drugs have been approved to treat cancer, but predicting which ones will help a particular patient is an inexact science at best.
A new device developed at MIT may change that. The implantable device, about the size of the grain of rice, can carry small doses of up to 30 different drugs. After implanting it in a tumor and letting the drugs diffuse into the tissue, researchers can measure how effectively each one kills the patient’s cancer cells.
Such a device could eliminate much of the guesswork now involved in choosing cancer treatments, says Oliver Jonas, a postdoc at MIT’s Koch Institute for Integrative Cancer Research and lead author of a paper describing the device in the April 22 online edition of Science Translational Medicine.
“You can use it to test a patient for a range of available drugs, and pick the one that works best,” Jonas says.
The paper’s senior authors are Robert Langer, the David H. Koch Professor at MIT and a member of the Koch Institute, the Institute for Medical Engineering and Science, and the Department of Chemical Engineering; and Michael Cima, the David H. Koch Professor of Engineering at MIT and a member of the Koch Institute and the Department of Materials Science and Engineering.
Putting the lab in the patient
Most of the commonly used cancer drugs work by damaging DNA or otherwise interfering with cell function. Recently, scientists have also developed more targeted drugs designed to kill tumor cells that carry a specific genetic mutation. However, it is usually difficult to predict whether a particular drug will be effective in an individual patient.
In some cases, doctors extract tumor cells, grow them in a lab dish, and treat them with different drugs to see which ones are most effective. However, this process removes the cells from their natural environment, which can play an important role in how a tumor responds to drug treatment, Jonas says.
“The approach that we thought would be good to try is to essentially put the lab into the patient,” he says. “It’s safe and you can do all of your sensitivity testing in the native microenvironment.”
The device, made from a stiff, crystalline polymer, can be implanted in a patient’s tumor using a biopsy needle. After implantation, drugs seep 200 to 300 microns into the tumor, but do not overlap with each other. Any type of drug can go into the reservoir, and the researchers can formulate the drugs so that the doses that reach the cancer cells are similar to what they would receive if the drug were given by typical delivery methods such as intravenous injection.
After one day of drug exposure, the implant is removed, along with a small sample of the tumor tissue surrounding it, and the researchers analyze the drug effects by slicing up the tissue sample and staining it with antibodies that can detect markers of cell death or proliferation.
Ranking cancer drugs
To test the device, the researchers implanted it in mice that had been grafted with human prostate, breast, and melanoma tumors. These tumors are known to have varying sensitivity to different cancer drugs, and the MIT team’s results corresponded to those previously seen differences.
The researchers then tested the device with a type of breast cancer known as triple negative, which lacks the three most common breast cancer markers: estrogen receptor, progesterone receptor, and Her2. This form of cancer is particularly aggressive, and none of the drugs used against it are targeted to a specific genetic marker.
Using the device, the researchers found that triple negative tumors responded differently to five of the drugs commonly used to treat them. The most effective was paclitaxel, followed by doxorubicin, cisplatin, gemcitabine, and lapatinib. They found the same results when delivering these drugs by intravenous injection, suggesting that the device is an accurate predictor of drug sensitivity.
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- Global Mice Model Market Outlook, 2019 to 2025 - Increasing Number of Personalized Medicine Spurs Market Demand - ResearchAndMarkets.comon November 29, 2019 at 9:30 am
DUBLIN--(Business Wire)--The "Mice Model - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering. The Mice Model market worldwide is projected to grow by ...
- Global Anatomic Pathology Market Forecast to 2024: Growing Focus on Personalized Medicineon November 27, 2019 at 5:30 am
The growth in this market is attributed to the high incidence of cancer and other target diseases, availability of reimbursement, and the growing focus on personalized medicine. In addition, emerging ...
- Intermountain launches pediatric center for personalized medicineon November 26, 2019 at 9:41 pm
A new Center for Personalized Medicine, located at Intermountain Primary Children’s Hospital in Salt Lake City, will deliver targeted therapies to critically ill kids, based on their genetic makeup.
- Research Led by City of Hope’s Bart O. Roep, Ph.D., Advances Personalized Medicine for Children With Type 1 Diabeteson November 22, 2019 at 4:50 pm
The study characterizes those differences in children with T1D, which represents an important first step toward personalized medicine for this patient population. Published in Diabetologia, the ...
- Organ-on-Chip Systems Enable Personalized Medicineon November 21, 2019 at 9:28 pm
Recent advances in stem cell technology allow researchers to create disease models for personalized medicine. SEMI spoke with Thomas Pauwelyn, Postdoctoral Researcher at imec, about trends in medical ...
- BRIEF—CarThera and Kiyatec collaborate on personalized medicine for glioblastomaon November 18, 2019 at 9:23 am
US biotech Kiyatec and France’s CarThera have entered into a clinical collaboration for the purpose of advancing innovation and improving treatments for patients diagnosed with glioblastoma, a highly ...
- Personalized Medicine Market By Product, Geography and Forecast 2019 – 2026on November 13, 2019 at 2:34 am
Nov 13, 2019 (Market Prediction via COMTEX) -- Acumen Research and Consulting has announced the addition of the “Personalized Medicine Market” report to their offering. The Personalized Medicine ...
- Global Personalized Medicine Market Advancement, Size, Growth, Access and Forecast 2019-2025 | Key Players – Abbott, Amgen, Astellas Pharma and Moreon November 13, 2019 at 1:50 am
QY Research offers an overarching research and analysis-based study on the global Personalized Medicine market, covering growth prospects, market development potential, profitability, supply and ...
- Personalized Medicine Market Comprehensive Insights Of Recent Developmentson November 11, 2019 at 10:30 pm
The report is readily available and can be dispatched immediately after payment confirmation.
- Advancing Personalized Medicine Through Predictionon November 11, 2019 at 4:00 pm
Dr. Griswold: University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216. Personalized medicine is the tailoring of medical treatment to each individual patient. Everyone ...
via Bing News